title: Sustained-release fampridine for symptomatic treatment of multiple sclerosis.
abstract: OBJECTIVE
  To review the pharmacology, pharmacokinetics, clinical trials, and adverse effects of sustained-release (SR) fampridine in patients with multiple sclerosis (MS).
  
  
  METHODS
  An English-language human data search was done using PubMed/MEDLINE (1966-August 2008) to retrieve relevant material using the search terms fampridine-SR, 4-aminopyridine, and multiple sclerosis. References of selected articles and information from the drug developer were used to further identify pertinent trials.
  
  
  METHODS
  Article selection was based primarily on studies that evaluated the pharmacokinetics, safety, and efficacy of fampridine-SR in patients with MS. Relevant meeting abstracts were also included as part of the analysis.
  
  
  RESULTS
  Fampridine-SR is a sustained-release, orally administered potassium-channel blocker acting in the central nervous system to enhance conduction in demyelinated axons. Several small trials have evaluated the safety and efficacy of fampridine-SR in patients with MS to improve their walking ability. Data from a recent large Phase 3 trial indicated that walking speed improved in 42.9% of patients with MS who were treated with fampridine-SR compared with 9.3% of those who received placebo (p < 0.001). Treatment-related adverse events associated with the use of fampridine-SR include dizziness, insomnia, nausea, and paresthesia. More severe adverse events, such as seizure, have occurred in patients receiving doses higher than those currently recommended.
  
  
  CONCLUSIONS
  Positive results from 2 Phase 3 clinical trials have put fampridine-SR on the path toward approval as a medication for improving walking speed and lower extremity strength in patients with MS.
authors.affiliation: Skaggs School of Pharmacy, The University of Montana, USA.
authors.forename: Anne R
authors.initials: AR
authors.lastname: Korenke
authors.forename: Michael P
authors.initials: MP
authors.lastname: Rivey
authors.forename: Douglas R
authors.initials: DR
authors.lastname: Allington
mesh_terms: D015761:4-Aminopyridine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000284:Administration, Oral; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D006801:Humans; D035002:Lower Extremity / Q000503:physiopathology; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000503:physiopathology; D053580:Muscle Strength / Q000187:drug effects; D026902:Potassium Channel Blockers / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016138:Walking
chemical_list: D003692:Delayed-Action Preparations; D026902:Potassium Channel Blockers; D015761:4-Aminopyridine